SEC Form 4 · accession 0001562180-18-002941
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rajesh Malik
Officer — Ch. Medical Officer & SVP R&D
Period of report
Jun 8, 2018
Accepted (ET)
Jun 11, 2018 · 10:51 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2018 | M | 4,200 | $0.39 | A | 8,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $0.39 | Jun 8, 2018 | M | 4,200 | D | — | Jul 11, 2024 | Common Stock | 4,200 | 103,744 | D |
Explanation of responses
- F1The shares underlying this option vested as to 25% of the shares on July 1, 2015 with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.